Adia Nutrition, Inc. reports sharply higher activity but continued losses for the three months ended March 31, 2026. Revenue rose to $176,275, mainly from medical procedures of MS patients and sales of biologics, producing gross profit of $67,577.
The company recorded a net loss of $162,525 and an accumulated deficit of $16,136,007, and its 10-Q states there is “substantial doubt” about its ability to continue as a going concern. Cash was $136,716 with total assets of $776,868 and total liabilities of $1,197,067, including a related-party line of credit of $723,656. As of March 31, 2026, 94,404,696 Class A common shares were outstanding.
ADIA Nutrition, Inc. filed its annual report, detailing a transition from a former shell into an operating regenerative-medicine and biologics business focused on stem-cell therapies and supplements. In 2025, the company generated $700,508 in revenue, mainly from sales of biologics and medical procedures, but recorded a net loss of $395,464 and an accumulated deficit of $15,973,482. Management’s auditors raised substantial doubt about ADIA’s ability to continue as a going concern. ADIA operates FDA-registered perinatal tissue products under Section 361, runs a Winter Park, Florida clinic, and uses a related-party credit line and small equity raises to fund operations while it scales its stem-cell and supplement activities.
Adia Nutrition, Inc. files a Form 10 to register its Common A Stock under the Exchange Act and describe its transition from a dormant shell into an operating regenerative medicine and supplements business. After court-appointed custodianship and several control changes, the company now runs Adia Med clinics and Adia Labs, focusing on autologous stem cell procedures and umbilical cord stem cell biologics such as AdiaVita and AdiaLink, alongside an 18% stake in supplement seller Cement Factory.
Revenue grew to $637,145 for the nine months ended September 30, 2025, mainly from biologic product sales and medical procedures, but the company still recorded a net loss and has an accumulated deficit over $15 million, leading auditors to raise substantial doubt about its ability to continue as a going concern. Operations depend heavily on a related-party credit line, a third‑party lab, and navigating complex FDA and AATB rules for human tissue products. The filing also highlights significant regulatory, competitive, liquidity and penny‑stock risks, as well as concentrated voting control through a single preferred share class.